Tekla Life Sciences Investors
HQL · NYSE
9/30/2024 | 9/30/2023 | 9/30/2022 | 9/30/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.02 | -0.13 | 0.01 | -0.16 |
| FCF Yield | 0.00% | 0.00% | 0.00% | 0.00% |
| EV / EBITDA | 4.85 | 7.06 | -3.56 | 7.37 |
| Quality | ||||
| ROIC | 18.01% | -1.30% | -24.86% | 12.10% |
| Gross Margin | 100.00% | 46.41% | 82.58% | 86.50% |
| Cash Conversion Ratio | – | – | – | – |
| Growth | ||||
| Revenue 3-Year CAGR | 39.60% | -4.36% | -6.57% | 164.23% |
| Free Cash Flow Growth | 0.00% | 0.00% | 0.00% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | 0.00 | -0.00 | -0.11 | 0.02 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.97 | 46.75 | -328.31 | -7.81 |